Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS

Retrovirology

Volumn 4, Issue , 2007, Pages

  Savarino, Andrea ^a   Pistello, Mauro ^b   D'Ostilio, Daniela ^a   Zabogli, Elisa ^b   Taglia, Fabiana ^a   Mancini, Fabiola ^a   Ferro, Stefania ^c   Matteucci, Donatella ^b   De Luca, Laura ^c   Barreca, Maria Letizia ^c   Ciervo, Alessandra ^a   Chimirri, Alba ^c   Ciccozzi, Massimo ^a   Bendinelli, Mauro ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHI 1010; CHI 1019; CIRCULAR DNA; INTEGRASE INHIBITOR; L 870 810; TRANSPOSASE; UNCLASSIFIED DRUG; VIRUS DNA; INTEGRASE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CELL CULTURE; COMPUTER PROGRAM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FELINE IMMUNODEFICIENCY VIRUS; GENE SEQUENCE; GENETIC ALGORITHM; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; LENTIVIRINAE; LYMPHOBLASTOID CELL LINE; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROVIRUS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIMULATION; STRUCTURE ACTIVITY RELATION; TRANSPOSON; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CAT; CAT DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; FEMALE; GENETICS; MOLECULAR GENETICS; PHYSIOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE; VIROLOGY;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELINE LENTIVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CATS; CELL LINE, TUMOR; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; INTEGRASE INHIBITORS; INTEGRASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NAPHTHYRIDINES; SEQUENCE ALIGNMENT; VIRAL PROTEINS; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 39449128792     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-79     Document Type: Article

References (50)

1. Savarino A A historical sketch of the discovery and development of HIV-1 integrase inhibitors Expert Opin Investig Drugs 2006, 15:1507-22. 17107277
2. Cyranoski D Animal research: Primates in the frame Nature 2006, 444:812-3. 17167452
3. Sparger EE FIV as a model for HIV: An overview In vivo models of HIV disease and control Springer Science+ Bussiness Media Friedman H, Specter S, Bendinelli M 2006 149-237.
4. Vahlenkamp TW Tompkins MB Tompkins WAF FIV as a model for AIDS pathogenesis studies In vivo models of HIV disease and control Springer Science+ Business Media Friedman H, Specter S, Bendinelli M 2006 239-273.
5. Driscoll CA Menotti-Raymond M Roca AL Hupe K Johnson WE Geffen E Harley EH Delibes M Pontier D Kitchener AC Yamaguchi N O'Brien SJ Macdonald DW The Near Eastern origin of cat domestication Science 2007, 317:519-23. 17600185
6. Dunham S Jarrett O FIV as a model for AIDS vaccine studies In vivo models of HIV disease and control Springer Science+ Business Media Friedman H, Specter S, Bendinelli M 2006 293-332.
7. Bisset LR Lutz H Böni J Hofmann-Lehmann R Lüthy R Schüpbach J Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication Antiviral Res 2002, 53:35-45. 11684314
8. Hartmann K Stengel C FIV as a model for HIV treatment In vivo models of HIV disease and control Springer Science+ Business Media Friedman H, Specter S, Bendinelli M 2006 333-364.
9. Auwerx J Esnouf R De Clercq E Balzarini J Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors Mol Pharmacol 2004, 65:244-51. 14722257
10. Lin YC Beck Z Morris GM Olson AJ Elder JH Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases J Virol 2003, 77:6589-600. 156162 12767979
11. Cassone A Cauda R HIV proteinase inhibitors: Do they really work against Candida in a clinical setting? Trends Microbiol 2002, 10:177-8. 11912024
12. Savarino A Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza J Clin Virol 2005, 34:170-8. 15893956
13. Lucia MB Savarino A Straface E Golotta C Rastrelli E Matarrese P Rutella S Malorni W Cauda R Role of lymphocyte multidrug resistance protein 1 in HIV infection: Expression, function, and consequences of inhibition J Acquir Immune Defic Syndr 2005, 40:257-66. 16249698
14. Savarino A Lucia MB Rastrelli E Rutella S Golotta C Morra E Tamburrini E Perno CF Boelaert JR Sperber K Cauda R Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors J Acquir Immune Defic Syndr 2004, 35:223-32. 15076236
15. Grinsztejn B Nguyen BY Katlama C Gatell JM Lazzarin A Vittecoq D Gonzalez CJ Chen J Harvey CM Isaacs RD Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial Lancet 2007, 369:1261-9. 17434401
16. Dayam R Al-Mawsawi LQ Neamati N HIV-1 integrase inhibitors: An emerging clinical reality Drugs R D 2007, 8:155-168. 17472411
17. Shibagaki Y Holmes ML Appa RS Chow SA Characterization of feline immunodeficiency virus integrase and analysis of functional domains Virology 1997, 230:1-10. 9126257
18. Vink C van der Linden KH Plasterk RH Activities of the feline immunodeficiency virus integrase protein produced in Escherichia coli J Virol 1994, 68:1468-74. 236602 8107210
19. Goldgur Y Craigie R Cohen GH Fujiwara T Yoshinaga T Fujishita T Sugimoto H Endo T Murai H Davies DR Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design Proc Natl Acad Sci USA 1999, 96:13040-3. 23896 10557269
20. Barreca ML De Luca L Iraci N Chimirri A Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase J Med Chem 2006, 49:3994-7. 16789757
21. Johnson AA Marchand C Patil SS Costi R Di Santo R Burke TR Jr Pommier Y Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays Mol Pharmacol 2007, 71:893-901. 17172465
22. Savarino A In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate Retrovirology 2007, 4:21. 1847836 17374162
23. Foley BT An overview of the molecular phylogeny of lentiviruses HIV sequence compendium Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N. Mex Kuiken C, Foley B, Freed E, Hahn B, Korber B, Marx PA, McCutchan F, Mellors JW, Mullins JI, Sodroski J, Wolinksy S 2000 35-43
24. Renoux-Elbé C Cheynier R Wain-Hobson S Phylogeny derived from coding retroviral genome organization J Mol Evol 2002, 54:376-85. 11847563
25. Conference Reports for NATAP 14th CROI Conference on Retroviruses and Opportunistic Infections Los Angeles http://www.natap.org/2007/CROI/ croi_61.htm 25-28 Feb 2007
26. Hazuda DJ Anthony NJ Gomez RP Jolly SM Wai JS Zhuang L Fisher TE Embrey M Guare JP Jr Egbertson MS Vacca JP Huff JR Felock PJ Witmer MV Stillmock KA Danovich R Grobler J Miller MD Espeseth AS Jin L Chen IW Lin JH Kassahun K Ellis JD Wong BK Xu W Pearson PG Schleif WA Cortese R Emini E Summa V Holloway MK Young SD A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase Proc Natl Acad Sci USA 2004, 101:11233-8. 509174 15277684
27. Dicker IB Samanta HK Hong Y Tian Y Banville J Remillard RR Walker MA Langley DR Krystal MR Changes to the HIV LTR and to HIV integrase differentially impact HIV integrase assembly, activity and the binding of strand transfer inhibitors J Biol Chem 2007.
28. O'Brien SJ Troyer JL Roelke M Plagues and adaptation: Lessons from the Felidae models for SARS and AIDS Biol Conserv 2006, 131:255-267.
29. Maignan S Guilloteau JP Zhou-Liu Q Clement-Mella C Mikol V Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases J Mol Biol 1998, 282:359-368. 9735293
30. Rice PA Baker TA Comparative architecture of transposase and integrase complexes Nat Struct Biol 2001, 8 302-7.
31. Barreca ML Ferro S Rao A De Luca L Zappala M Monforte AM Debyser Z Witvrouw M Chimirri A Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors J Med Chem 2005, 48:7084-8. 16250669
32. U.S. National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov
33. Pistello M Cammarota G Nicoletti E Matteucci D Curcio M Del Mauro D Bendinelli M Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B J Gen Virol 1997, 78:2247-57. 9292012
34. Del Mauro D Matteucci D Giannecchini S Maggi F Pistello M Bendinelli M Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates J Virol 1998, 72:2199-207. 109516 9499077
35. Thompson JD Gibson TJ Plewniak F Jeanmougin F Higgins DG The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools Nucleic Acids Res 1997, 25:4876-82. 147148 9396791
36. Hall TA Bioedit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT Nucl Acids Symp 1999, 41:95-98.
37. Swofford DL PAUP* 4.0: Phylogenetic analysis using parsimony (*and other methods), version 4.0b10 Sunderland, MA: Sinauer Associates Inc; 1999.
38. RCSB Protein Data Bank http://www.rcsb.org/pdb/home/home.do
39. ExPASy Proteomics Server http://www.expasy.org
40. VEGA ZZ Homepage http://www.ddl.unimi.it/vega/index2.htm
41. Main Page- MolProbity http://molprobity.biochem.duke.edu/
42. WHAT IF Web Interface http://swift.cmbi.kun.nl/WIWWWI/
43. Molecular Networks Gmbh http://www.molecular-networks.com/online_demos/ corina_demo.html
44. Brook BR Bruccoleri RE Olafson BD States DJ Swaminathan S Karplus M CHARMM: A program for macromolecular energy, minimization and dynamic calculations J Comput Chem 1983, 4:187-217.
45. Matteucci D Mazzetti P Baldinotti F Zaccaro L Bendinelli M The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation Vet Immunol Immunopathol 1995, 46:71-82. 7618261
46. Yamamoto JK Ackley CD Zochlinski H Louie H Pembroke E Torten M Hansen H Munn R Okuda T Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines Intervirology 1991, 32:361-75. 1657826
47. Lombardi S Massi C Indino E La Rosa C Mazzetti P Falcone ML Rovero P Fissi A Pieroni O Bandecchi P Esposito F Tozzini F Bendinelli M Garzelli C Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides Virology 1996, 220:274-84. 8661378
48. Savarino A Gennero L Chen HC Serrano D Malavasi F Boelaert JR Sperber K Anti-HIV effects of chloroquine: Mechanisms of inhibition and spectrum of activity AIDS 2001, 15:2221-9. 11698694
49. Ciervo A Petrucca A Cassone A Identification and quantification of Chlamydia pneumoniae in human atherosclerotic plaques by LightCycler real-time-PCR Mol Cell Probes 2003, 17:107-11. 12788032
50. PyMOL Homepage http://pymol.sourceforge.net/